
Alpha Tau Medical Ltd. (NASDAQ:DRTS) shares are trading higher after the company announced FDA approval of its IDE application to initiate its multi-center pivotal study for the treatment of recurrent cutaneous Squamous Cell Carcinoma using the Alpha DaRT.
The clinical study, entitled “A Prospective Multicenter, Pivotal, Single Arm, Open Label Clinical Study to Assess the Efficacy and Safety of Intratumoral Alpha DaRT for the Treatment of Patients with Recurrent Cutaneous Squamous Cell Carcinoma” has been approved to enroll up to 86 U.S. patients at up to 20 institutions in the U.S.